

PATENT
1110-0279P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Yoshiyuki UENO

Conf.: 3959

Appl. No.: 09/700,338

Group: 1648

Filed: November 14, 2000

Examiner: U. Winkler

For: PREVENTIVES/REMEDIES FOR HEPATIC
CIRRHOSISREPLY UNDER 37 C.F.R. §1.111Assistant Commissioner for Patents
Washington, DC 20231

January 2, 2003

Sir:

In reply to the Office Action dated October 2, 2002, the following remarks are respectfully submitted in connection with the above-identified application.

REMARKSRejection under 35 U.S.C. §103

Claims 8 and 10-16 have been rejected under 35 U.S.C. §103 as being obvious over Kondo et al., in view of Harada et al. and Shirakawa et al.

Kondo et al. is asserted to teach that the administration of a soluble form of Fas to HbsAg transgenic mice prevented CTL-induced liver disease. Kondo et al. is further asserted to teach inhibition of disease progression with two animal models for hepatitis. Kondo et al. is asserted differ from the invention in

#8
Recov
5.9.3